Novartis disclosed a mid-stage eczema drug win and detailed its autoimmune CAR-T restart plans after a rocky quarter, while trimming the upper end of its sales-growth guidance through 2031. The update frames eczema progress as a near-term momentum driver and positions autoimmune cell therapy as a strategic rebuild following earlier setbacks. The company’s commentary ties operating focus to inflammation and immunology execution, with CAR-T work centered on resuming activity and refining development steps. For investors, the guidance tweak points to continued caution around the timing and scale of future launches. The ecosystem-level takeaway is that large-platform cell therapy programs remain sensitive to execution milestones and that eczema remains an important value lever for Novartis’ dermatology and immunology pipeline. In practical terms, the next catalysts for investors and clinicians will likely be updated trial timelines for autoimmune CAR-T and confirmatory readouts for eczema efficacy and safety.